Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Marginal zone lymphoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Transformation to diffuse large B-cell lymphoma in a minority.
No standard sequence of therapies is proven by randomised trials.
Rare sites (lung, skin, dura) are managed by extrapolation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
MCL and MZL indications voluntarily withdrawn after confirmatory trials missed
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
A milestone in how this cancer is treated.
Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.
Three-year progression-free survival 80.